ESLA (Estrella Immunopharma, Inc.) Stock Market Reviews

crown

search

Read and share opinions on ESLA (Estrella Immunopharma, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock mar

ESLA

Estrella Immunopharma, Inc.

clarify Biotechnology

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients
Nov 3, 2025
Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements
Oct 6, 2025
Is Estrella Immunopharma (NASDAQ:ESLA) In A Good Position To Deliver On Growth Plans?
Aug 14, 2025
Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Jun 5, 2025
Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing
Jun 3, 2025
Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s Lymphomas
May 29, 2025
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners
Mar 5, 2025
Estrella Immunopharma completes first dose cohort in STARLIGHT trial
Feb 22, 2025
Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort
Feb 21, 2025
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital
Feb 19, 2025

Reviews